ZNF592

Across TCGA pan-cancer cohorts, ZNF592 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of ZNF592’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ZNF592 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ZNF592 is over-expressed in tumor, although a few such as KICH and BRCA show the opposite, repressed pattern.

HNSC, LIHC, and STAD are the cancer types where ZNF592 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZNF592 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.662	<.001	12	view →
LIHC	Female	II,III,IV	+0.872	<.001	9	view →
STAD	Male	II,III,IV	+1.089	<.001	6	view →
CHOL	All	All	+1.584	<.001	5	view →
KICH	All	All	−0.640	<.001	4	view →
BRCA	Female	All	−0.231	<.001	4	view →
THCA	All	All	−0.242	.011	3	view →
LUAD	Female	All	−0.479	<.001	2	view →
KIRC	Female	All	+0.379	.012	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

ZNF592–HNSC

Open the HNSC breakdown →